Global variation in CYP2C8-CYP2C9 functional haplotypes
- PMID: 19381162
- PMCID: PMC2782405
- DOI: 10.1038/tpj.2009.10
Global variation in CYP2C8-CYP2C9 functional haplotypes
Abstract
We have studied the global frequency distributions of 10 single nucleotide polymorphisms (SNPs) across 132 kb of CYP2C8 and CYP2C9 in approximately 2500 individuals representing 45 populations. Five of the SNPs were in noncoding sequences; the other five involved the more common missense variants (four in CYP2C8, one in CYP2C9) that change amino acids in the gene products. One haplotype containing two CYP2C8 coding variants and one CYP2C9 coding variant reaches an average frequency of 10% in Europe; a set of haplotypes with a different CYP2C8 coding variant reaches 17% in Africa. In both cases these haplotypes are found in other regions of the world at <1%. This considerable geographic variation in haplotype frequencies impacts the interpretation of CYP2C8/CYP2C9 association studies, and has pharmacogenomic implications for drug interactions.
Figures


Similar articles
-
Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.Pharmacogenomics J. 2012 Jun;12(3):267-76. doi: 10.1038/tpj.2010.89. Epub 2010 Dec 21. Pharmacogenomics J. 2012. PMID: 21173785
-
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.Eur J Clin Pharmacol. 2010 Dec;66(12):1199-205. doi: 10.1007/s00228-010-0864-8. Epub 2010 Jul 28. Eur J Clin Pharmacol. 2010. PMID: 20665013
-
Haplotype structures of common variants of CYP2C8, CYP2C9, and ADRB1 genes in a South Indian population.Genet Test Mol Biomarkers. 2011 Jun;15(6):407-13. doi: 10.1089/gtmb.2010.0170. Epub 2011 Mar 4. Genet Test Mol Biomarkers. 2011. PMID: 21375401
-
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.Mol Diagn Ther. 2006;10(1):29-40. doi: 10.1007/BF03256440. Mol Diagn Ther. 2006. PMID: 16646575 Review.
-
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20. doi: 10.1517/17425250902970998. Expert Opin Drug Metab Toxicol. 2009. PMID: 19422321 Review.
Cited by
-
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.Breast Cancer Res Treat. 2012 Jul;134(1):401-10. doi: 10.1007/s10549-012-2054-0. Epub 2012 Apr 18. Breast Cancer Res Treat. 2012. PMID: 22527101 Free PMC article.
-
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.Pharmacogenomics J. 2022 Dec;22(5-6):284-293. doi: 10.1038/s41397-022-00288-2. Epub 2022 Sep 6. Pharmacogenomics J. 2022. PMID: 36068297 Free PMC article.
-
Proposed nomenclature for microhaplotypes.Hum Genomics. 2016 Jun 17;10(1):16. doi: 10.1186/s40246-016-0078-y. Hum Genomics. 2016. PMID: 27316555 Free PMC article.
-
CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.Haematologica. 2011 Oct;96(10):1557-9. doi: 10.3324/haematol.2011.042572. Epub 2011 Jun 17. Haematologica. 2011. PMID: 21685474 Free PMC article.
-
Association of CYP2C9∗3 and CYP2C8∗3 Non-Functional Alleles with Ibuprofen-Induced Upper Gastrointestinal Toxicity in a Saudi Patient.Case Rep Med. 2023 Jul 21;2023:6623269. doi: 10.1155/2023/6623269. eCollection 2023. Case Rep Med. 2023. PMID: 37520310 Free PMC article.
References
-
- Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther. 2005;77:341–352. - PubMed
-
- Kirchheiner J, Tsahuridu M, Jabrane W, Roots I, Brockmoller J. The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Per Med. 2004;1:63–84. - PubMed
-
- Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1–16. - PubMed
-
- Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11:597–607. - PubMed
-
- Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 1996;6:429–439. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases